Brief: Vivesto Signs Deal With Kazia Therapeutics To Acquire Full Cantrixil Rights
31/03/2025 07:15
March 31 (Reuters) - Vivesto AB VIVE.ST: VIVESTO SIGNS DEAL WITH KAZIA THERAPEUTICS TO ACQUIRE FULL CANTRIXIL RIGHTS TO ACQUIRE FULL RIGHTS, INCLUDING ALL INTELLECTUAL PROPERTY AND TRADEMARKS RIGHTS FOR DRUG CANDIDATE CANTRIXIL FOR 1 MUSD Source text: ID:nMFN3Zy89Y Further company coverage: VIVE.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Vivesto AB
See all newsBrief: Vivesto Reports Positive Topline Results From Paccal Vet Study In Cats
Brief: Vivesto Says Topline Results For Paccal Vet 'Positive'
Brief: Vivesto Q2 Operating Loss At SEK 8.6 Mln
Brief: Vivesto: Positive Results From Exploratory Study With Cantrixil
Brief: Vivesto Appoints Björn Svanström As CFO